ASCO GU 2026 Prostate Cancer

Viewing 1-20 of 100 articles

ASCO GU 2026: Imaging Meets Genomics in Treatment-Naïve Prostate Cancer: SUVmax on PSMA PET as a Biomarker of Genomic Classifier Risk

ASCO GU 2026: Community Social Vulnerability and Clinical Risk-Based Care Implementation for Black Men with Prostate Cancer Treated in

ASCO GU 2026: Physician Perspectives on the Implementability of a Cardiovascular Risk Score for Prostate Cancer: A PRISM-guided Evaluation.

ASCO GU 2026: Prognostic Significance of Depressive Symptoms in Men with Advanced Prostate Cancer: Results from the IRONMAN Registry

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

ASCO GU 2026: OMAHA-003: Phase 3 Trial of CYP11A1 Inhibitor Opevesostat versus ARPI Switch in Participants with mCRPC After ARPI and Taxane-Based Chemotherapy

ASCO GU 2026: The LuxAR-02 Phase II Study of Luxdegalutamide in Combination with 177Lu-PSMA-617 in Patients with PSMA-Positive mCRPC

ASCO GU 2026: Clinical Outcomes Among Patients with mHSPC in Contemporary Real-World US Clinical Practice: A Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis

ASCO GU 2026: Association Between Genomic Classifier Scores and Initial Management of Localized Prostate Cancer in a Population-Based Cohort in the United States

ASCO GU 2026: Discussant: Improving Outcomes for Radiotherapy

ASCO GU 2026: Association of a Post-Prostatectomy Digital Pathology-Based MMAI Biomarker with Nodal and Extrapelvic Metastasis on PET/CT at the Time of Biochemical Recurrence and Event-Free Survival Following Salvage Radiotherapy

ASCO GU 2026: EXTRA-PC: A Phase II Trial of Masofaniten (EPI-7386) and Enzalutamide with ADT for Patients with mHSPC

ASCO GU 2026: External Validation of a Digital Pathology-Based MMAI-Derived Prognostic Biomarker in the Randomized Phase III CHHiP Trial

ASCO GU 2026: Genomic Risk Classifier Performance in PET-Guided Post-Prostatectomy Patients: Secondary Analysis of a Randomized Trial

ASCO GU 2026: OMAHA-004: Phase 3 Trial of CYP11A1 Inhibitor Opevesostat versus ARPI Switch in Participants with mCRPC After a Prior ARPI

ASCO GU 2026: ADT and Radiotherapy with or Without Cabazitaxel in Very High Risk Localized Prostate Cancer: First Results of the PEACE-2 Randomized Phase III Trial

ASCO GU 2026: IDeate-Prostate02: A Phase 1/2, Open-Label Umbrella Substudy of Ifinatamab Deruxtecan–Based Treatment Combinations or as Monotherapy in Participants with Previously Treated mCRPC

ASCO GU 2026: Discussant: Choosing a Treatment Strategy for Patients with mCRPC – All in or Play the Long Game?

ASCO GU 2026: 177Lu-PSMA-617 in Combination with ARPI versus 177Lu-PSMA-617 Alone for the Treatment of mCRPC: A Real-World Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis

ASCO GU 2026: Dose Optimization and PSMA Receptor Intensification with 177Lu-PSMA-597 in mCRPC: The Randomized Phase II OPTIMAL-PSMA Trial

1
2
3
4
5